Abstract
The majority of patients with myelodysplastic syndromes (MDS) become transfusion-dependent during the course of disease and may thus develop transfusional iron overload. As a further contributor to iron overload there is increased absorption of dietary iron from the gut, as a consequence of ineffective erythropoiesis. Compared with thalassemia, it is less clear how frequent patients with MDS develop clinical complications of iron overload, and whether the accumulation of iron shortens their survival. This review aims to summarize our current knowledge of the detrimental effects of transfusional iron overload in MDS, point out the risks associated with ironinduced oxidative stress, describe the tools available for diagnosing iron overload, indicate the treatment options with currently available iron chelators, and discuss the measurement of labile plasma iron (LPI) as a tool to monitor the efficacy of iron chelation therapy.
Keywords: Iron overload, myelodysplastic syndromes, oxidative stress, non-transferrin-bound iron, labile plasma iron, iron chelation, dietary iron, transfusional iron overload, erythropoiesis, hemoglobin
Current Pharmaceutical Design
Title:Pathophysiological and Clinical Aspects of Iron Chelation Therapy in MDS
Volume: 18 Issue: 22
Author(s): Norbert Gattermann
Affiliation:
Keywords: Iron overload, myelodysplastic syndromes, oxidative stress, non-transferrin-bound iron, labile plasma iron, iron chelation, dietary iron, transfusional iron overload, erythropoiesis, hemoglobin
Abstract: The majority of patients with myelodysplastic syndromes (MDS) become transfusion-dependent during the course of disease and may thus develop transfusional iron overload. As a further contributor to iron overload there is increased absorption of dietary iron from the gut, as a consequence of ineffective erythropoiesis. Compared with thalassemia, it is less clear how frequent patients with MDS develop clinical complications of iron overload, and whether the accumulation of iron shortens their survival. This review aims to summarize our current knowledge of the detrimental effects of transfusional iron overload in MDS, point out the risks associated with ironinduced oxidative stress, describe the tools available for diagnosing iron overload, indicate the treatment options with currently available iron chelators, and discuss the measurement of labile plasma iron (LPI) as a tool to monitor the efficacy of iron chelation therapy.
Export Options
About this article
Cite this article as:
Gattermann Norbert, Pathophysiological and Clinical Aspects of Iron Chelation Therapy in MDS, Current Pharmaceutical Design 2012; 18 (22) . https://dx.doi.org/10.2174/1381612811209023222
DOI https://dx.doi.org/10.2174/1381612811209023222 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
A Review on the Phytochemicals, Ethnomedicine Uses and Pharmacology of Ficus Species
Current Traditional Medicine Common Variants for Heart Failure
Current Genomics Stem Cell Based Preclinical Drug Development and Toxicity Prediction
Current Pharmaceutical Design Pathogenesis of Stroke-Like Episodes in MELAS: Analysis of Neurovascular Cellular Mechanisms
Current Neurovascular Research Inherited Muscle Diseases Towards Improvements of the Mouse Model Catalogue
Current Genomics Mitochondrial Dysfunction and Endoplasmic Reticulum Stress in Diabetes
Current Pharmaceutical Design Levosimendan Reduces Prostaglandin F2a-dependent Vasoconstriction in Physiological Vessels and After Experimentally Induced Subarachnoid Hemorrhage
Current Neurovascular Research Novel Carriers for Coenzyme Q10 Delivery
Current Drug Delivery Phytochemicals and Cancer Stem Cells: A Pancreatic Cancer Overview
Current Chemical Biology Exploring the Role of Gene Therapy for Neurological Disorders
Current Gene Therapy Inhibition of Tumor Angiogenesis by Antibodies, Synthetic Small Molecules and Natural Products
Current Medicinal Chemistry Toll-Like Receptors and Myocardial Ischemia/Reperfusion, Inflammation, and Injury
Current Cardiology Reviews Pharmacological and Non Pharmacological Strategies in the Management of Coronary Artery Disease and Chronic Kidney Disease
Current Cardiology Reviews Cardiac Regeneration: Stem Cells and Beyond
Current Medicinal Chemistry Dopamine: The Forgotten Felon in Type 2 Diabetes
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Physical Activity and Diabetic Cardiomyopathy: Myocardial Adaptation Depending on Exercise Load
Current Diabetes Reviews Strain Imaging Echocardiography: What Imaging Cardiologists Should Know
Current Cardiology Reviews Cellular and Molecular Mechanisms of Low Cardiac Output Syndrome after Pediatric Cardiac Surgery
Current Vascular Pharmacology Mitochondria, Cellular Stress Resistance, Somatic Cell Depletion and Lifespan
Current Aging Science The Delivery of Personalised, Precision Medicines <i>via</i> Synthetic Proteins
Drug Delivery Letters